| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults. Despite important progress in the molecular characterization of GBMs in recent years, treatment efficacy has only improved marginally and median survival after diagnosis is still limited to about 14 months. GBMs are highly vascularised tumors and endothelial cell proliferation is one of the neuropathological hallmarks of the disease. Therefore the concept of interfering with blood vessel formation has long been proposed as a promising strategy against GBM. Recent clinical trials have shown good radiological response rates with bevacizumab, an antibody against vascular endothelial growth factor (VEGF). Yet, it is currently not known through which biological mechanisms bevacizumab exerts its effect, and whether it has a true anti-tumor effect.
- Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults. Despite important progress in the molecular characterization of GBMs in recent years, treatment efficacy has only improved marginally and median survival after diagnosis is still limited to about 14 months. GBMs are highly vascularised tumors and endothelial cell proliferation is one of the neuropathological hallmarks of the disease. Therefore the concept of interfering with blood vessel formation has long been proposed as a promising strategy against GBM. Recent clinical trials have shown good radiological response rates with bevacizumab, an antibody against vascular endothelial growth factor (VEGF). Yet, it is currently not known through which biological mechanisms bevacizumab exerts its effect, and whether it has a true anti-tumor effect. (en)
- Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults. Despite important progress in the molecular characterization of GBMs in recent years, treatment efficacy has only improved marginally and median survival after diagnosis is still limited to about 14 months. GBMs are highly vascularised tumors and endothelial cell proliferation is one of the neuropathological hallmarks of the disease. Therefore the concept of interfering with blood vessel formation has long been proposed as a promising strategy against GBM. Recent clinical trials have shown good radiological response rates with bevacizumab, an antibody against vascular endothelial growth factor (VEGF). Yet, it is currently not known through which biological mechanisms bevacizumab exerts its effect, and whether it has a true anti-tumor effect. (cs)
|
| Title
| - Multi-modal imaging and pharmacokinetic modeling shed light on mechanism of action of anti-angiogenic therapy in malignant gliomas
- Multi-modal imaging and pharmacokinetic modeling shed light on mechanism of action of anti-angiogenic therapy in malignant gliomas (en)
- Multi-modal imaging and pharmacokinetic modeling shed light on mechanism of action of anti-angiogenic therapy in malignant gliomas (cs)
|
| skos:prefLabel
| - Multi-modal imaging and pharmacokinetic modeling shed light on mechanism of action of anti-angiogenic therapy in malignant gliomas
- Multi-modal imaging and pharmacokinetic modeling shed light on mechanism of action of anti-angiogenic therapy in malignant gliomas (en)
- Multi-modal imaging and pharmacokinetic modeling shed light on mechanism of action of anti-angiogenic therapy in malignant gliomas (cs)
|
| skos:notation
| - RIV/00216305:26220/10:PU89748!RIV11-GA0-26220___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00216305:26220/10:PU89748
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - GBM, VEGF, DCE-MRI, DWI, MRS (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...vavai/riv/projekt
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...iv/tvurceVysledku
| - Bartoš, Michal
- Jiřík, Radovan
- Keunen, Olivier
- Taxt, Torfinn
- Bjerkvig, Rolf
- Thorsen, Frits
- Abdulrahim, Siti Aminah
- Fack, Fred
- Johansson, Mikael
- Niclou, Simone
- Oudin, Anais
- Sanzey, Morgane
|
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)